Chennai, Dec 19: In a compelling example of how precision oncology is transforming cancer care, Apollo Athenaa Women’s Cancer Centres successfully treated a 69-year-old international patient from Kazakhstan diagnosed with Stage IV non-small cell lung cancer (NSCLC) using targeted therapy, avoiding the need for chemotherapy, radiotherapy, or invasive procedures.
Ms Maya, a spirited grandmother and avid walker, began experiencing persistent breathlessness. A former smoker, she was diagnosed with advanced lung cancer and underwent two rounds of chemotherapy in her home country. As her symptoms worsened, her family travelled over 2,500 kilometres to India seeking advanced treatment options.
Upon evaluation at Apollo Athenaa, doctors found that the cancer had spread to both lungs, the pleura, lymph nodes, and the brain, raising concerns about potential neurological complications and the likelihood of aggressive interventions, including brain radiotherapy.
A tissue biopsy followed by comprehensive genomic profiling revealed the presence of an EML4-ALK fusion, a genetic alteration known to respond exceptionally well to targeted therapy. Based on this finding, the oncology team initiated a personalised treatment plan using a single oral targeted therapy tablet taken once daily, replacing conventional chemotherapy and radiation.
Within weeks of starting treatment, Ms Maya showed remarkable clinical improvement. Her breathlessness reduced significantly, energy levels improved, and she was able to resume her daily walks. Follow-up imaging demonstrated an excellent response across all disease sites, including the brain, achieved without radiotherapy.
Commenting on the case, Dr. Jyoti Wadhwa, Lead Medical and Precision Oncology, Apollo Athenaa Women’s Cancer Centres, said,
“Ms Maya’s journey highlights the power of precision oncology. By identifying actionable genetic alterations, we can offer highly effective, personalised treatments that reduce the need for aggressive therapies. Her recovery with a single targeted pill demonstrates how modern cancer care can be scientifically advanced, less toxic, and deeply compassionate.”
Sharing her experience, Ms Maya said,
“I travelled to Delhi with fear in my heart. But Dr. Jyoti Wadhwa and the team at Apollo Athenaa gave me hope when everything felt uncertain. I never imagined that one pill a day could give me back my breath, my walks, and my strength. I feel like I have my life again.”
Ms Maya’s recovery underscores the extraordinary progress in targeted cancer therapies and reinforces Apollo Athenaa’s commitment to delivering cutting-edge, patient-centric oncology care that restores not just health, but hope and quality of life.